Abstract
Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.
Keywords: Arthritis, gene therapy, adenovirus, adeno-associated virus, lentivirus, osteoarthritis, interleukin-1, tumor necrosis factor
Current Gene Therapy
Title: Perspectives on the Use of Gene Therapy for Chronic Joint Diseases
Volume: 8 Issue: 4
Author(s): Steven C. Ghivizzani, Elvire Gouze, Jean-Noel Gouze, Jesse D. Kay, Marsha L. Bush, Rachael S. Watson, Padraic P. Levings, David M. Nickerson, Patrick T. Colahan, Paul D. Robbins and Christopher H. Evans
Affiliation:
Keywords: Arthritis, gene therapy, adenovirus, adeno-associated virus, lentivirus, osteoarthritis, interleukin-1, tumor necrosis factor
Abstract: Advances in molecular and cellular biology have identified a wide variety of proteins including targeted cytokine inhibitors, immunomodulatory proteins, cytotoxic mediators, angiogenesis inhibitors, and intracellular signalling molecules that could be of great benefit in the treatment of chronic joint diseases, such as osteo- and rheumatoid arthritis. Unfortunately, protein-based drugs are difficult to administer effectively. They have a high rate of turnover, requiring frequent readministration, and exposure in non-diseased tissue can lead to serious side effects. Gene transfer technologies offer methods to enhance the efficacy of protein-based therapies, enabling the body to produce these molecules locally at elevated levels for extended periods. The proof of concept of gene therapies for arthritis has been exhaustively demonstrated in multiple laboratories and in numerous animal models. This review attempts to condense these studies and to discuss the relative benefits and limitations of the methods proposed and to discuss the challenges toward translating these technologies into clinical realities.
Export Options
About this article
Cite this article as:
Ghivizzani C. Steven, Gouze Elvire, Gouze Jean-Noel, Kay D. Jesse, Bush L. Marsha, Watson S. Rachael, Levings P. Padraic, Nickerson M. David, Colahan T. Patrick, Robbins D. Paul and Evans H. Christopher, Perspectives on the Use of Gene Therapy for Chronic Joint Diseases, Current Gene Therapy 2008; 8 (4) . https://dx.doi.org/10.2174/156652308785160638
DOI https://dx.doi.org/10.2174/156652308785160638 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Cytokine-Induced Inflammatory Liver Injuries
Current Molecular Medicine Neurological Disorders in Pregnancy
Current Women`s Health Reviews Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Editorial The Role of Mesenchymal Stem Cells in Bone Regeneration: Underlying Mechanisms and Systemic Regulatory Factors
Current Stem Cell Research & Therapy Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy GluVII:06 - A Highly Conserved and Selective Anchor Point for Non-Peptide Ligands in Chemokine Receptors
Current Topics in Medicinal Chemistry The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Cytotoxicity and Anti-Inflammatory Effects of Polyherbal Formulations, Joint Pain Spl and Rumalaya Forte on Lipopolysaccharide Induced Inflammation in IC-21 Macrophages
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Response to Rituximab: Has the Original Hypothesis Been Confirmed?
Current Pharmaceutical Design Antioxidants and Inflammatory Disease: Synthetic and Natural Antioxidants with Anti-Inflammatory Activity
Combinatorial Chemistry & High Throughput Screening Editorial [Hot topic: General Aspects of Biologic Agents in Rheumatology (Guest Editor: Omer Faruk Sendur)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets Current Studies of Osteoclastogenesis and Potential Drug Targets
Current Drug Targets An in silico Workflow that Yields Experimentally Comparable Inhibitors for Human Dihydroorotate Dehydrogenase
Current Computer-Aided Drug Design Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients
Current Pharmacogenomics